Monday, July 11, 2016

Audentes Therapeutics Sets IPO Pricing Range

San Francisco-based gene therapy developer Audentes Therapeutics has set the IPO pricing range for its upcoming IPO, saying in a filing this morning that it is hoping to sell 5,000,000 shares of its common stock at between $14.00 and $16.00 per share. The company has applied to list on the NASDAQ Global Market as BOLD. The IPO is being underwritten by BofA Merrill Lynch, Cowen and Company, Piper Jaffray, and Wedbush PacGrow. Audentes is backed by OrbiMed, 5AM Ventures, Versant Ventures, Sofinnova Venture Partners, Deerfield Management, and others.